Do analysts prefer LUCY or PSTV?

Plus Therapeutics has a consensus price target of $56.40, indicating a potential upside of 1,282.35%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Plus Therapeutics is more favorable than Innovative Eyewear. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innovative Eyewear 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Plus Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43

Does the media prefer LUCY or PSTV?

In the previous week, Innovative Eyewear had 1 more articles in the media than Plus Therapeutics. MarketBeat recorded 3 mentions for Innovative Eyewear and 2 mentions for Plus Therapeutics. Innovative Eyewear's average media sentiment score of 0.54 beat Plus Therapeutics' score of 0.47 indicating that Innovative Eyewear is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innovative Eyewear 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to NMTC or LUCY?

In the previous week, Innovative Eyewear had 1 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 3 mentions for Innovative Eyewear and 2 mentions for NeuroOne Medical Technologies. NeuroOne Medical Technologies' average media sentiment score of 0.94 beat Innovative Eyewear's score of 0.54 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroOne Medical Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innovative Eyewear 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend POAI or LUCY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Innovative Eyewear 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts rate CTSO or LUCY?

Cytosorbents presently has a consensus price target of $5.38, suggesting a potential upside of 1,282.10%. Given Cytosorbents' stronger consensus rating and higher possible upside, equities analysts clearly believe Cytosorbents is more favorable than Innovative Eyewear. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytosorbents 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Innovative Eyewear 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts prefer LFWD or LUCY?

Lifeward presently has a consensus target price of $10.00, indicating a potential upside of 28.04%. Given Lifeward's stronger consensus rating and higher possible upside, equities analysts plainly believe Lifeward is more favorable than Innovative Eyewear. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lifeward 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Innovative Eyewear 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Innovative Eyewear (LUCY) Competitors

$0.87 -0.09 (-8.88%)

Closing price 07/15/2026 04:00 PM Eastern

Extended Trading

$0.88 +0.01 (+0.72%)

As of 07:38 AM Eastern

Compare

LUCY vs. PSTV, NMTC, POAI, CTSO, and LFWD

Should you buy Innovative Eyewear stock or one of its competitors? MarketBeat compares Innovative Eyewear with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Innovative Eyewear include Plus Therapeutics (PSTV), NeuroOne Medical Technologies (NMTC), Predictive Oncology (POAI), Cytosorbents (CTSO), and Lifeward (LFWD). These companies are all part of the "medical equipment" industry.

How does Innovative Eyewear compare to Plus Therapeutics?

Innovative Eyewear (NASDAQ:LUCY) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

In the previous week, Innovative Eyewear had 1 more articles in the media than Plus Therapeutics. MarketBeat recorded 3 mentions for Innovative Eyewear and 2 mentions for Plus Therapeutics. Innovative Eyewear's average media sentiment score of 0.54 beat Plus Therapeutics' score of 0.47 indicating that Innovative Eyewear is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innovative Eyewear	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Plus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Innovative Eyewear has higher earnings, but lower revenue than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Innovative Eyewear, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innovative Eyewear	$2.66M	2.10	-$7.59M	-$1.69	N/A
Plus Therapeutics	$5.21M	5.39	-$22.39M	-$2.30	N/A

Plus Therapeutics has a consensus price target of $56.40, indicating a potential upside of 1,282.35%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Plus Therapeutics is more favorable than Innovative Eyewear.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innovative Eyewear	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Plus Therapeutics has a net margin of -230.24% compared to Innovative Eyewear's net margin of -272.42%. Innovative Eyewear's return on equity of -83.37% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innovative Eyewear	-272.42%	-83.37%	-76.02%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

1.0% of Innovative Eyewear shares are owned by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are owned by institutional investors. 1.7% of Innovative Eyewear shares are owned by company insiders. Comparatively, 2.5% of Plus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Innovative Eyewear has a beta of 2.71, meaning that its stock price is 171% more volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

Summary

Plus Therapeutics beats Innovative Eyewear on 9 of the 16 factors compared between the two stocks.

How does Innovative Eyewear compare to NeuroOne Medical Technologies?

NeuroOne Medical Technologies (NASDAQ:NMTC) and Innovative Eyewear (NASDAQ:LUCY) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

NeuroOne Medical Technologies has a net margin of -68.35% compared to Innovative Eyewear's net margin of -272.42%. Innovative Eyewear's return on equity of -83.37% beat NeuroOne Medical Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroOne Medical Technologies	-68.35%	-99.43%	-70.40%
Innovative Eyewear	-272.42%	-83.37%	-76.02%

NeuroOne Medical Technologies has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Innovative Eyewear has a beta of 2.71, suggesting that its stock price is 171% more volatile than the broader market.

16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. Comparatively, 1.0% of Innovative Eyewear shares are owned by institutional investors. 11.8% of NeuroOne Medical Technologies shares are owned by insiders. Comparatively, 1.7% of Innovative Eyewear shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Innovative Eyewear had 1 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 3 mentions for Innovative Eyewear and 2 mentions for NeuroOne Medical Technologies. NeuroOne Medical Technologies' average media sentiment score of 0.94 beat Innovative Eyewear's score of 0.54 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroOne Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innovative Eyewear	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeuroOne Medical Technologies has higher revenue and earnings than Innovative Eyewear. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Innovative Eyewear, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroOne Medical Technologies	$12.10M	1.80	-$3.61M	-$0.85	N/A
Innovative Eyewear	$2.66M	2.10	-$7.59M	-$1.69	N/A

NeuroOne Medical Technologies presently has a consensus price target of $11.67, indicating a potential upside of 364.81%. Given NeuroOne Medical Technologies' stronger consensus rating and higher probable upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than Innovative Eyewear.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Innovative Eyewear	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

NeuroOne Medical Technologies beats Innovative Eyewear on 11 of the 16 factors compared between the two stocks.

How does Innovative Eyewear compare to Predictive Oncology?

Predictive Oncology (NASDAQ:POAI) and Innovative Eyewear (NASDAQ:LUCY) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

Predictive Oncology has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market. Comparatively, Innovative Eyewear has a beta of 2.71, meaning that its share price is 171% more volatile than the broader market.

Innovative Eyewear has a net margin of -272.42% compared to Predictive Oncology's net margin of -5,065.23%. Innovative Eyewear's return on equity of -83.37% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-5,065.23%	-732.73%	-235.55%
Innovative Eyewear	-272.42%	-83.37%	-76.02%

Innovative Eyewear has higher revenue and earnings than Predictive Oncology. Predictive Oncology is trading at a lower price-to-earnings ratio than Innovative Eyewear, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.66M	14.29	-$12.66M	-$13.50	N/A
Innovative Eyewear	$2.66M	2.10	-$7.59M	-$1.69	N/A

In the previous week, Innovative Eyewear had 3 more articles in the media than Predictive Oncology. MarketBeat recorded 3 mentions for Innovative Eyewear and 0 mentions for Predictive Oncology. Innovative Eyewear's average media sentiment score of 0.54 beat Predictive Oncology's score of 0.00 indicating that Innovative Eyewear is being referred to more favorably in the news media.

Company	Overall Sentiment
Predictive Oncology	Neutral
Innovative Eyewear	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Innovative Eyewear	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 1.0% of Innovative Eyewear shares are held by institutional investors. 1.2% of Predictive Oncology shares are held by company insiders. Comparatively, 1.7% of Innovative Eyewear shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Innovative Eyewear beats Predictive Oncology on 12 of the 14 factors compared between the two stocks.

How does Innovative Eyewear compare to Cytosorbents?

Cytosorbents (NASDAQ:CTSO) and Innovative Eyewear (NASDAQ:LUCY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Cytosorbents has a net margin of -31.85% compared to Innovative Eyewear's net margin of -272.42%. Innovative Eyewear's return on equity of -83.37% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-31.85%	-235.57%	-37.88%
Innovative Eyewear	-272.42%	-83.37%	-76.02%

Innovative Eyewear has lower revenue, but higher earnings than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than Innovative Eyewear, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.66	-$8.20M	-$0.19	N/A
Innovative Eyewear	$2.66M	2.10	-$7.59M	-$1.69	N/A

In the previous week, Innovative Eyewear had 2 more articles in the media than Cytosorbents. MarketBeat recorded 3 mentions for Innovative Eyewear and 1 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 1.32 beat Innovative Eyewear's score of 0.54 indicating that Cytosorbents is being referred to more favorably in the media.

Company	Overall Sentiment
Cytosorbents	Positive
Innovative Eyewear	Positive

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 1.0% of Innovative Eyewear shares are owned by institutional investors. 7.8% of Cytosorbents shares are owned by insiders. Comparatively, 1.7% of Innovative Eyewear shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cytosorbents has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market. Comparatively, Innovative Eyewear has a beta of 2.71, indicating that its share price is 171% more volatile than the broader market.

Cytosorbents presently has a consensus price target of $5.38, suggesting a potential upside of 1,282.10%. Given Cytosorbents' stronger consensus rating and higher possible upside, equities analysts clearly believe Cytosorbents is more favorable than Innovative Eyewear.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Innovative Eyewear	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Cytosorbents beats Innovative Eyewear on 10 of the 16 factors compared between the two stocks.

How does Innovative Eyewear compare to Lifeward?

Lifeward (NASDAQ:LFWD) and Innovative Eyewear (NASDAQ:LUCY) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

26.8% of Lifeward shares are owned by institutional investors. Comparatively, 1.0% of Innovative Eyewear shares are owned by institutional investors. 1.5% of Lifeward shares are owned by company insiders. Comparatively, 1.7% of Innovative Eyewear shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Innovative Eyewear has lower revenue, but higher earnings than Lifeward. Innovative Eyewear is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifeward	$22.03M	1.00	-$19.91M	-$19.66	N/A
Innovative Eyewear	$2.66M	2.10	-$7.59M	-$1.69	N/A

Lifeward presently has a consensus target price of $10.00, indicating a potential upside of 28.04%. Given Lifeward's stronger consensus rating and higher possible upside, equities analysts plainly believe Lifeward is more favorable than Innovative Eyewear.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifeward	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Innovative Eyewear	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Lifeward has a net margin of -123.66% compared to Innovative Eyewear's net margin of -272.42%. Innovative Eyewear's return on equity of -83.37% beat Lifeward's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifeward	-123.66%	-243.14%	-97.39%
Innovative Eyewear	-272.42%	-83.37%	-76.02%

In the previous week, Innovative Eyewear had 2 more articles in the media than Lifeward. MarketBeat recorded 3 mentions for Innovative Eyewear and 1 mentions for Lifeward. Lifeward's average media sentiment score of 1.53 beat Innovative Eyewear's score of 0.54 indicating that Lifeward is being referred to more favorably in the media.

Company	Overall Sentiment
Lifeward	Very Positive
Innovative Eyewear	Positive

Lifeward has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, Innovative Eyewear has a beta of 2.71, suggesting that its stock price is 171% more volatile than the broader market.

Summary

Lifeward and Innovative Eyewear tied by winning 8 of the 16 factors compared between the two stocks.

Get Innovative Eyewear News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LUCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LUCY vs. The Competition

Export

Metric	Innovative Eyewear	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.13M	$8.31B	$6.77B	$12.55B
Dividend Yield	N/A	2.57%	2.68%	9.45%
P/E Ratio	-0.52	15.51	27.07	24.35
Price / Sales	2.10	7.72	494.08	76.87
Price / Cash	N/A	18.01	48.63	60.00
Price / Book	0.52	3.33	10.82	6.31
Net Income	-$7.59M	$228.19M	$3.59B	$331.55M
7 Day Performance	-18.44%	-2.50%	-1.78%	-0.71%
1 Month Performance	1.42%	-1.91%	3.73%	0.16%
1 Year Performance	-59.78%	-0.34%	27.45%	19.66%

Innovative Eyewear Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LUCY Innovative Eyewear	0.9052 of 5 stars	$0.87 -8.9%	N/A	-59.6%	$6.13M	$2.66M	N/A	9	Gap Up
PSTV Plus Therapeutics	2.4872 of 5 stars	$3.84 -2.2%	$56.40 +1,370.7%	-48.5%	$26.39M	$5.21M	N/A	20
NMTC NeuroOne Medical Technologies	2.8573 of 5 stars	$3.00 -0.7%	$11.67 +288.9%	-40.7%	$26.10M	$12.10M	N/A	20
POAI Predictive Oncology	N/A	$7.39 -12.1%	N/A	-40.9%	$25.08M	$1.66M	N/A	30
CTSO Cytosorbents	3.4099 of 5 stars	$0.40 -2.4%	$5.38 +1,253.9%	-62.2%	$24.95M	$37.20M	N/A	220	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LUCY) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Innovative Eyewear (LUCY) Competitors

LUCY vs. PSTV, NMTC, POAI, CTSO, and LFWD

How does Innovative Eyewear compare to Plus Therapeutics?

Summary

How does Innovative Eyewear compare to NeuroOne Medical Technologies?

Summary

How does Innovative Eyewear compare to Predictive Oncology?

Summary

How does Innovative Eyewear compare to Cytosorbents?

Summary

How does Innovative Eyewear compare to Lifeward?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCY vs. The Competition

Innovative Eyewear Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Innovative Eyewear (LUCY) Competitors

LUCY vs. PSTV, NMTC, POAI, CTSO, and LFWD

How does Innovative Eyewear compare to Plus Therapeutics?

Does the media prefer LUCY or PSTV?

Which has stronger valuation and earnings, LUCY or PSTV?

Do analysts prefer LUCY or PSTV?

Is LUCY or PSTV more profitable?

Do institutionals & insiders believe in LUCY or PSTV?

Which has more volatility & risk, LUCY or PSTV?

Summary

How does Innovative Eyewear compare to NeuroOne Medical Technologies?

Is NMTC or LUCY more profitable?

Which has more volatility and risk, NMTC or LUCY?

Do insiders and institutionals have more ownership in NMTC or LUCY?

Does the media refer more to NMTC or LUCY?

Which has stronger earnings and valuation, NMTC or LUCY?

Do analysts rate NMTC or LUCY?

Summary

How does Innovative Eyewear compare to Predictive Oncology?

Which has more volatility and risk, POAI or LUCY?

Is POAI or LUCY more profitable?

Which has stronger valuation & earnings, POAI or LUCY?

Does the media favor POAI or LUCY?

Do analysts recommend POAI or LUCY?

Do institutionals & insiders believe in POAI or LUCY?

Summary

How does Innovative Eyewear compare to Cytosorbents?

Is CTSO or LUCY more profitable?

Which has higher earnings & valuation, CTSO or LUCY?

Does the media favor CTSO or LUCY?

Do insiders & institutionals hold more shares of CTSO or LUCY?

Which has more risk & volatility, CTSO or LUCY?

Do analysts rate CTSO or LUCY?

Summary

How does Innovative Eyewear compare to Lifeward?

Do insiders and institutionals believe in LFWD or LUCY?

Which has preferable valuation & earnings, LFWD or LUCY?

Do analysts prefer LFWD or LUCY?

Is LFWD or LUCY more profitable?

Does the media prefer LFWD or LUCY?

Which has more risk & volatility, LFWD or LUCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCY vs. The Competition

Innovative Eyewear Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools